Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arbutus BiopharmaABUS +0.22%51 Earnings per Share (Diluted) is $0.83 as of Mar. 2026. GuruFocus rates ABUS with a GF Score™ of 51/100 and a GF Value™ of $50.35 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,164 Biotechnology companies, Arbutus Biopharma ranks better than 73.97% on this metric.
Arbutus Biopharma's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.88.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.84.
During the past 3 years, the average EPS without NRIGrowth Rate was 36.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 31.60% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 16.80% per year.
During the past 13 years, Arbutus Biopharma's highest 3-Year average EPS without NRI Growth Rate was 47.50% per year. The lowest was -36.60% per year. And the median was 2.00% per year.
Arbutus Biopharma (NAS:ABUS) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Arbutus Biopharma Earnings per Share (Diluted) Related Terms
Arbutus Biopharma Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma Earnings per Share (Diluted) Chart
ABUS vs TBPH, ANNX, SANA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Arbutus Biopharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's PE Ratio falls into.
Arbutus Biopharma Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Arbutus Biopharma's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.83
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.83 mean?
Arbutus Biopharma (ABUS) has a Earnings per Share (Diluted) of $0.83 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Arbutus Biopharma and its competitors. According to the industry distribution chart, Arbutus Biopharma ranks #303 out of 1164 companies in the Biotechnology industry, placing it in the top 26%.
Is Arbutus Biopharma's Earnings per Share (Diluted) too high?
Arbutus Biopharma's current Earnings per Share (Diluted) is $0.83. The Biotechnology industry median Earnings per Share (Diluted) is 16.20. Arbutus Biopharma's value of $0.83 is 94.9% below this industry median. Based on the distribution chart, Arbutus Biopharma ranks #303 out of 1164 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Earnings per Share (Diluted) compare to TBPH and ANNX?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #303 out of 1164 companies for Earnings per Share (Diluted). This puts Arbutus Biopharma in the upper half of its industry. The industry median Earnings per Share (Diluted) is 16.20. Arbutus Biopharma's value of $0.83 is 94.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,164 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current Earnings per Share (Diluted) of $0.83 is 94.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Arbutus Biopharma and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Earnings per Share (Diluted) is $0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $50.35, compared to a current price of $4.62 — trading 90.8% below its estimated fair value. The current Earnings per Share (Diluted) is $0.83 and 94.9% below the Biotechnology industry median of 16.20. Arbutus Biopharma's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Earnings per Share (Diluted) is $0.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.62 is trading 90.8% below its estimated GF Value™ of $50.35.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
Earnings per Share (Diluted): $0.83
GF Value™: $50.35 vs. price of $4.62 (90.8% below fair value)
Industry Position: 94.9% below the Biotechnology median (#303 of 1164)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score
Get the complete analysis for ABUS
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
